Randomised, Double Blind, Placebo-controlled, Incomplete Block, 3-way Cross-over Study to Evaluate Efficacy and Safety of 4 Doses of Glycopyrronium Bromide (CHF5259) DPI in Moderate to Severe Patients With COPD
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 262
- 试验地点
- 30
- 主要终点
- FEV1 AUC0-12h normalised by time (L)
研究概览
简要总结
The study was designed to investigate the efficacy and safety of different doses CHF5259 a long acting muscarinic antagonist in patients with moderate to severe COPD.
详细描述
Outpatients attending the hospital clinics/study centres will be recruited. Patients with moderate to severe COPD airflow obstruction according to GOLD 2015 criteria.
A total of approximately 300 patients will be enrolled.
Patients are followed during 3 different treatment periods of 4 weeks separated each by 3 weeks wash-out period. The study lasts approximately 21 weeks for each patient and a total of 11 clinic visits is performed during the study.
The primary endpoint is the Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) 0-12h normalised by time on Day 28.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged ≥ 40 years
- •Patients with a diagnosis of stable COPD at least 12 months before screening visit.
- •Current smoker or ex-smoker with a smoking history of at least 10 pack-years
- •A post-bronchodilator FEV1 ≥ 40% and ≤70% of the predicted normal value and,
- •a post-bronchodilator FEV1/FVC < 0.7 and,
- •a change in FEV1 from the pre-bronchodilator value (reversibility) of at least 5% at screening
- •Patients under bronchodilators with long-acting muscarinic antagonist or long-acting 2 agonist (monotherapy or dual therapy), or patients under ICS + LABA (long-acting beta2-agonist) or ICS (Inhaled Corticosteroids) + LAMA (Long Acting Muscarinic Agonist) for at least 4 weeks prior to screening.
- •(Patients with a FEV1<50% of the predicted value and a history of 1 exacerbation within the last 12 months must have been treated with ICS+LABA or ICS+LAMA before screening)
- •Ability and cooperative attitude to understand and to perform required outcome measurements of the protocol (e.g. spirometry manoeuvres) and ability to understand the risks involved. Ability to be trained to use the dry powder inhalers.
排除标准
- •Diagnosis of asthma or other respiratory disorders (other than COPD) which may interfere with data interpretation according to the investigator's opinion.
- •Patients had a COPD exacerbation or a lower respiratory tract infection within 8 weeks prior to screening, or during the run-in period, that resulted in the use of an antibiotic, or oral or parenteral corticosteroids, or hospitalisation.
- •Patients with a history of ≥ 2 exacerbations within the last 12 months prior to screening.
- •Patients treated with oral/parenteral β2-agonists or nebulised bronchodilators or phosphodiesterase inhibitors or who received LABA/LAMA/ICS treatment therapy in the 4 weeks prior to screening and during the run-in period.
- •Patient is on an inhaled corticosteroid that has been initiated, or the effective dose has been changed, within 4 weeks prior to screening or during the run-in period (patients on stable dose of ICS for at least 4 weeks prior to screening are allowed).
- •Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.
- •Patients with known respiratory disorders other than COPD including but not limited to alpha1 antitrypsin deficiency, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension and interstitial lung disease.
- •Patients with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic.
- •Patients who have unstable concurrent disease that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study;
- •Patients who have a concomitant disease of poor prognosis (e.g., cancer...).
- •Patients who have clinically significant cardiovascular condition diagnosed in the last 6 months
- •Patients with known atrial fibrillation (AF):
- •Paroxysmal Atrial Fibrillation
- •Long standing persistent.
- •Patients with a clinically significant abnormal 12-lead ECG that might, in the judgment of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study.
- •Patients whose electrocardiogram 12-lead ECG shows a QTcF>450 ms for males or QTcF > 470 ms for females.
- •Patients with clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study.
- •Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS they are willing to use a highly effective birth control methods
- •Patients known to have intolerance/hypersensitivity or any contra-indication to treatment with M3 Antagonist or any of the excipients contained in the formulations used in the study.
- •Patients who have evidence of alcohol or drug abuse, not compliant with the study protocol or not compliant with the study treatments according to investigator's judgment.
- •Patients with major surgery in the previous 3 months or planned during the trial which may affect patient's compliance in study procedures.
- •Patients who have participated in another clinical trial with an investigational drug in the 2 months preceding the screening.
研究组 & 干预措施
CHF5259 12.5 μg total daily dose
CHF5259 or Placebo administration:
Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI matched placebo twice a day
Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
Day 14: pre-dose spirometry
Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
干预措施: CHF5259 or Placebo administration (Drug)
CHF5259 25 μg total daily dose
CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI 6.25μg twice a day
Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
Day 14: pre-dose spirometry
Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
干预措施: CHF5259 or Placebo administration (Drug)
CHF5259 50 μg total daily dose
CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 12.5 μg + 1 puff of CHF5259 DPI 12.5 μg twice a day
Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
Day 14: pre-dose spirometry
Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
干预措施: CHF5259 or Placebo administration (Drug)
CHF5259 100μg total daily dose
CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment :1 puff of CHF5259 DPI 25 μg + 1 puff of CHF5259 DPI 25 μg twice a day
Interventions :
Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
Day 14: pre-dose spirometry
Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
干预措施: CHF5259 or Placebo administration (Drug)
CHF5259 matched Placebo BID
CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 2 puffs of CHF5259 DPI matched placebo twice a day
Interventions :
Day 1 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
Day 14: pre-dose spirometry
Day 28 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
干预措施: CHF5259 or Placebo administration (Drug)
结局指标
主要结局
FEV1 AUC0-12h normalised by time (L)
时间窗: Day 28
次要结局
- Change from baseline in morning pre-dose FEV1 (L)(Day 14)
- Peak0-4h effect in FEV1 (L)(Day 28)
- Adverse events and adverse drug reactions(Day 28)
- Change from baseline in morning pre-dose Forced Vital Capacity FVC (L)(Day 28)
- Change from baseline in morning pre-dose FVC (L)(Day 14)
- Change from baseline in morning pre-dose Inspiratory Capacity IC (L)(Day 28)
- Change from baseline in morning pre-dose IC (L)(Day 14)